The use of neuroproteomics in drug abuse research

Melinda E. Lull, Willard M. Freeman, Heather D. VanGuilder, Kent Vrana

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The number of discovery proteomic studies of drug abuse has begun to increase in recent years, facilitated by the adoption of new techniques such as 2D-DIGE and iTRAQ. For these new tools to provide the greatest insight into the neurobiology of addiction, however, it is important that the addiction field has a clear understanding of the strengths, limitations, and drug abuse-specific research factors of neuroproteomic studies. This review outlines approaches for improving animal models, protein sample quality and stability, proteome fractionation, data analysis, and data sharing to maximize the insights gained from neuroproteomic studies of drug abuse. For both the behavioral researcher interested in what proteomic study results mean, and for biochemists joining the drug abuse research field, a careful consideration of these factors is needed. Similar to genomic, transcriptomic, and epigenetic methods, appropriate use of new proteomic technologies offers the potential to provide a novel and global view of the neurobiological changes underlying drug addiction. Proteomic tools may be an enabling technology to identify key proteins involved in drug abuse behaviors, with the ultimate goal of understanding the etiology of drug abuse and identifying targets for the development of therapeutic agents.

Original languageEnglish (US)
Pages (from-to)11-22
Number of pages12
JournalDrug and alcohol dependence
Volume107
Issue number1
DOIs
StatePublished - Feb 1 2010

Fingerprint

Substance-Related Disorders
Proteomics
Research
Pharmaceutical Preparations
Two-Dimensional Difference Gel Electrophoresis
Technology
Neurobiology
Information Dissemination
Proteome
Fractionation
Epigenomics
Joining
Animals
Proteins
Animal Models
Research Personnel

All Science Journal Classification (ASJC) codes

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Lull, Melinda E. ; Freeman, Willard M. ; VanGuilder, Heather D. ; Vrana, Kent. / The use of neuroproteomics in drug abuse research. In: Drug and alcohol dependence. 2010 ; Vol. 107, No. 1. pp. 11-22.
@article{90d17df813a04af0a8de17e2e6f8a650,
title = "The use of neuroproteomics in drug abuse research",
abstract = "The number of discovery proteomic studies of drug abuse has begun to increase in recent years, facilitated by the adoption of new techniques such as 2D-DIGE and iTRAQ. For these new tools to provide the greatest insight into the neurobiology of addiction, however, it is important that the addiction field has a clear understanding of the strengths, limitations, and drug abuse-specific research factors of neuroproteomic studies. This review outlines approaches for improving animal models, protein sample quality and stability, proteome fractionation, data analysis, and data sharing to maximize the insights gained from neuroproteomic studies of drug abuse. For both the behavioral researcher interested in what proteomic study results mean, and for biochemists joining the drug abuse research field, a careful consideration of these factors is needed. Similar to genomic, transcriptomic, and epigenetic methods, appropriate use of new proteomic technologies offers the potential to provide a novel and global view of the neurobiological changes underlying drug addiction. Proteomic tools may be an enabling technology to identify key proteins involved in drug abuse behaviors, with the ultimate goal of understanding the etiology of drug abuse and identifying targets for the development of therapeutic agents.",
author = "Lull, {Melinda E.} and Freeman, {Willard M.} and VanGuilder, {Heather D.} and Kent Vrana",
year = "2010",
month = "2",
day = "1",
doi = "10.1016/j.drugalcdep.2009.10.001",
language = "English (US)",
volume = "107",
pages = "11--22",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

The use of neuroproteomics in drug abuse research. / Lull, Melinda E.; Freeman, Willard M.; VanGuilder, Heather D.; Vrana, Kent.

In: Drug and alcohol dependence, Vol. 107, No. 1, 01.02.2010, p. 11-22.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The use of neuroproteomics in drug abuse research

AU - Lull, Melinda E.

AU - Freeman, Willard M.

AU - VanGuilder, Heather D.

AU - Vrana, Kent

PY - 2010/2/1

Y1 - 2010/2/1

N2 - The number of discovery proteomic studies of drug abuse has begun to increase in recent years, facilitated by the adoption of new techniques such as 2D-DIGE and iTRAQ. For these new tools to provide the greatest insight into the neurobiology of addiction, however, it is important that the addiction field has a clear understanding of the strengths, limitations, and drug abuse-specific research factors of neuroproteomic studies. This review outlines approaches for improving animal models, protein sample quality and stability, proteome fractionation, data analysis, and data sharing to maximize the insights gained from neuroproteomic studies of drug abuse. For both the behavioral researcher interested in what proteomic study results mean, and for biochemists joining the drug abuse research field, a careful consideration of these factors is needed. Similar to genomic, transcriptomic, and epigenetic methods, appropriate use of new proteomic technologies offers the potential to provide a novel and global view of the neurobiological changes underlying drug addiction. Proteomic tools may be an enabling technology to identify key proteins involved in drug abuse behaviors, with the ultimate goal of understanding the etiology of drug abuse and identifying targets for the development of therapeutic agents.

AB - The number of discovery proteomic studies of drug abuse has begun to increase in recent years, facilitated by the adoption of new techniques such as 2D-DIGE and iTRAQ. For these new tools to provide the greatest insight into the neurobiology of addiction, however, it is important that the addiction field has a clear understanding of the strengths, limitations, and drug abuse-specific research factors of neuroproteomic studies. This review outlines approaches for improving animal models, protein sample quality and stability, proteome fractionation, data analysis, and data sharing to maximize the insights gained from neuroproteomic studies of drug abuse. For both the behavioral researcher interested in what proteomic study results mean, and for biochemists joining the drug abuse research field, a careful consideration of these factors is needed. Similar to genomic, transcriptomic, and epigenetic methods, appropriate use of new proteomic technologies offers the potential to provide a novel and global view of the neurobiological changes underlying drug addiction. Proteomic tools may be an enabling technology to identify key proteins involved in drug abuse behaviors, with the ultimate goal of understanding the etiology of drug abuse and identifying targets for the development of therapeutic agents.

UR - http://www.scopus.com/inward/record.url?scp=74749085217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74749085217&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2009.10.001

DO - 10.1016/j.drugalcdep.2009.10.001

M3 - Review article

C2 - 19926406

AN - SCOPUS:74749085217

VL - 107

SP - 11

EP - 22

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1

ER -